Imagine your body is like a complex machine with thousands of tiny switches and dials. This project looks at all those dials—from your DNA to the proteins in your blood—to find the exact ones that cause heart attacks. By spotting these patterns early, doctors can predict who is at risk long before a crisis happens.
Current heart attack prevention is limited because the genetic and environmental causes are too complex for standard tests. There is a critical need for precise, early-warning biomarkers to reduce the 18 million annual deaths from cardiovascular disease.
A high-throughput multi-omic analysis pipeline and machine learning algorithms to identify drug targets and risk scores.
If you are a drug discovery firm dealing with high failure rates in cardiovascular clinical trials — this project developed a high-throughput method to identify robust drug targets that could accelerate the creation of medicines to prevent heart attacks.
If you are a clinical laboratory dealing with imprecise heart disease screening — this project developed quantitative targeted proteomic assays and risk algorithms that allow for early detection of high-risk patients.
If you are a health-tech AI company dealing with the need for better predictive models for stroke and MI — this project developed machine learning algorithms using data from 1,000 individuals to create polygenic risk scores.
Based on available project data, the specific commercial pricing or implementation cost is not provided, as the project is currently in the research and development phase.
The project uses a dataset of 1,000 individuals from the MAMI study to identify targets that are intended to be applicable across all populations.
Based on available project data, specific licensing terms are not listed; however, the project aims to identify novel drug targets and biomarkers for clinical translation.
The project is developing quantitative targeted proteomic assays and risk algorithms designed for early risk prediction directly in the clinic.
The project period runs from 2023-10-01 to 2028-09-30, suggesting that validated results and assays will be finalized toward the end of this window.
The consortium is purely academic, consisting of 2 universities from Malta and the Netherlands. With 0% industry participation and no SMEs, the project is currently driven by basic research and bioinformatics rather than commercial product development, which may indicate a need for industrial partners for future translation.
Contact the research office at Universita Ta Malta
Contact us to find a commercial partner for this multi-omics pipeline.
